This pricing supplement, which is not complete and may be changed,
relates to an effective Registration Statement under the Securities
Act of 1933. This pricing supplement and the accompanying product
supplement, prospectus supplement and prospectus are not an offer
to sell these notes in any country or jurisdiction where such an
offer would not be permitted.

Linked to the Least Performing of the INDUSTRIAL SELECT SECTOR SPDR
FUND, the SPDR S&P BIOTECH ETF and the SPDR S&P REGIONAL
BANKING ETF
|
● |
Approximate 2 year
term if not
called prior to maturity. |
|
● |
Payments on the Notes will
depend on the individual performance of the INDUSTRIAL
SELECT SECTOR SPDR FUND, the SPDR S&P BIOTECH ETF and the SPDR
S&P REGIONAL BANKING ETF (each an “Underlying”). |
|
● |
Contingent coupon rate of 12.75%
per annum
(3.1875% per quarter)
payable
quarterly if the
Observation Value of each Underlying on the applicable
Observation Date is greater than or equal to 65% of its Starting
Value. |
|
● |
Beginning on July 28, 2022,
callable quarterly at our option for an amount
equal to the principal amount plus the relevant contingent coupon,
if otherwise payable. |
|
● |
Assuming the Notes are not
called prior to maturity, if any Underlying declines by more
than 35%
from its Starting Value, at maturity your investment will be
subject to 1:1 downside exposure to decreases in the value of the
Least Performing Underlying, with up to
100% of the
principal at risk; otherwise, at maturity you will receive the
principal amount. At maturity you will also receive the
final contingent coupon if the Observation
Value of each Underlying on the final
Observation Date is greater than or equal to 65% of its Starting
Value. |
|
● |
All payments on the Notes are
subject to the credit risk of BofA Finance LLC (“BofA Finance”), as
issuer of the Notes, and Bank of America Corporation (“BAC” or the
“Guarantor”), as guarantor of the Notes. |
|
● |
The Contingent Income Issuer
Callable Yield Notes Linked to the Least Performing of the
INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR S&P BIOTECH ETF
and the SPDR S&P REGIONAL BANKING ETF, due January 30, 2024
(the “Notes”) are
expected to price on January 25, 2022 and expected to issue on
January 28, 2022. |
|
● |
The Notes will not be listed
on any securities exchange. |
The initial estimated value of the Notes as of the pricing date
is expected to be between $900.00 and $950.00 per $1,000 in
principal amount of Notes, which is less than the public offering
price listed below. The actual value of your Notes at any time
will reflect many factors and cannot be predicted with accuracy.
See “Risk Factors” beginning on page PS-8 of this pricing
supplement and “Structuring the Notes” on page PS-22 of this
pricing supplement for additional information.
There are important differences between the Notes and a
conventional debt security. Potential purchasers of the Notes
should consider the information in “Risk Factors” beginning on page
PS-8 of this pricing supplement, page PS-5 of the accompanying
product supplement, page S-5 of the accompanying prospectus
supplement, and page 7 of the accompanying prospectus.
None of the Securities and Exchange Commission (the “SEC”), any
state securities commission, or any other regulatory body has
approved or disapproved of these securities or determined if this
pricing supplement and the accompanying product supplement,
prospectus supplement and prospectus is truthful or complete. Any
representation to the contrary is a criminal offense.
|
Public offering price(1) |
Underwriting discount(1)(2) |
Proceeds, before expenses, to BofA Finance(2) |
Per Note |
$1,000.00 |
$17.50 |
$982.50 |
Total |
|
|
|
(1) |
Certain dealers who purchase the Notes for sale to certain
fee-based advisory accounts may forgo some or all of their selling
concessions, fees or commissions. The public offering price for
investors purchasing the Notes in these fee-based advisory accounts
may be as low as $982.50 per $1,000 in principal amount of the
Notes. |
|
(2) |
The underwriting discount per $1,000 in principal amount of Notes
may be as high as $17.50, resulting in proceeds, before expenses,
to BofA Finance of as low as $982.50 per $1,000 in principal amount
of Notes.
|
The Notes and the related guarantee:
Are Not FDIC Insured |
Are Not Bank Guaranteed |
May Lose Value |
 |
Selling Agent |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Terms of the Notes
The Notes provide a quarterly Contingent Coupon Payment of $31.875
per $1,000 in principal amount of Notes on the applicable
Contingent Payment Date if, on the related quarterly Observation
Date, the Observation Value of each Underlying is greater
than or equal to its Coupon Barrier.
Prior to the maturity date, beginning on July 28, 2022 and on each
quarterly Call Date thereafter, we have the right to call all, but
not less than all, of the Notes at 100% of the principal amount,
together with the relevant Contingent Coupon Payment, if otherwise
payable. No further amounts will be payable following an Optional
Early Redemption. If the Notes are not called prior to maturity and
the Least Performing Underlying declines by more than 35% from its
Starting Value, there is full exposure to declines in the Least
Performing Underlying, and you will lose a significant portion or
all of your investment in the Notes. Otherwise, at maturity you
will receive the principal amount. At maturity you will also
receive the final Contingent Coupon Payment if the Observation
Value of each Underlying on the final Observation Date is
greater than or equal to its Coupon Barrier. It is possible that
the Notes will not pay any Contingent Coupon Payments, and you may
lose a significant portion or all of your investment in the Notes
at maturity. Any payments on the Notes will be calculated based on
$1,000 in principal amount of Notes and will depend on the
performance of the Underlyings, subject to our and BAC’s credit
risk.
Issuer: |
BofA Finance |
Guarantor: |
BAC |
Denominations: |
The Notes will be issued in minimum denominations of $1,000 and
whole multiples of $1,000 in excess thereof. |
Term: |
Approximately 2 years, unless previously called. |
Underlyings: |
The INDUSTRIAL SELECT SECTOR SPDR FUND (Bloomberg symbol: “XLI”),
the SPDR S&P BIOTECH ETF (Bloomberg symbol: “XBI”) and the SPDR
S&P REGIONAL BANKING ETF (Bloomberg symbol: “KRE”). |
Pricing
Date*: |
January 25, 2022 |
Issue
Date*: |
January 28, 2022 |
Valuation
Date*: |
January 25, 2024, subject to postponement as described under
“Description of the Notes—Certain Terms of the Notes—Events
Relating to Observation Dates” in the accompanying product
supplement. |
Maturity
Date*: |
January 30, 2024 |
Starting
Value: |
With respect to each Underlying, its Closing Market Price on the
pricing date. |
Observation
Value: |
With respect to each Underlying, its Closing Market Price on the
applicable Observation Date multiplied by its Price
Multiplier. |
Ending
Value: |
With respect to each Underlying, its Observation Value on the
Valuation Date. |
Price
Multiplier: |
With respect to each Underlying, 1, subject to adjustment for
certain events as described in “Description of the Notes —
Anti-Dilution and Discontinuance Adjustments Relating to ETFs”
beginning on page PS-27 of the accompanying product
supplement. |
Coupon
Barrier: |
With respect to each Underlying, 65% of its Starting Value. |
Threshold
Value: |
With respect to each Underlying, 65% of its Starting Value. |
Contingent
Coupon
Payment:
|
If, on any quarterly Observation Date, the Observation Value of
each Underlying is greater than or equal to its Coupon
Barrier, we will pay a Contingent Coupon Payment of $31.875 per
$1,000 in principal amount of Notes (equal to a rate of 3.1875% per
quarter or 12.75% per annum) on the applicable Contingent Payment
Date (including the Maturity Date). |
Optional Early
Redemption:
|
On any Call Date, we have the right to redeem all (but not less
than all) of the Notes at the Early Redemption Amount. No further
amounts will be payable following an Optional Early Redemption. We
will give notice to the trustee at least five business days but not
more than 60 calendar days before the applicable Call Date. |
Early Redemption
Amount:
|
For each $1,000 in principal amount of Notes, $1,000. The Early
Redemption Amount will also include the applicable Contingent
Coupon Payment if the Observation Value of each Underlying on the
corresponding Observation Date is greater than or equal to its
Coupon Barrier. |
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-2 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Redemption
Amount: |
If the Notes have not been called prior to maturity, the Redemption
Amount per $1,000 in principal amount of Notes will be: |
a) |
If the Ending Value of the Least Performing Underlying is greater
than or equal to its Threshold Value: |
|
|
$1,000; or |
b) |
If the Ending Value of the Least Performing Underlying is less than
its Threshold Value: |
|
|
 |
|
In this case, the Redemption Amount will be less than 65% of the
principal amount and you could lose up to 100% of your investment
in the Notes. |
The Redemption Amount will also include the final Contingent Coupon
Payment if the Ending Value of the Least Performing Underlying is
greater than or equal to its Coupon Barrier. |
Observation
Dates*: |
As set forth on page PS-4. |
Contingent
Payment
Dates*:
|
As set forth on page PS-4. |
Call
Dates*: |
The quarterly Contingent Payment Dates beginning on July 28, 2022
and ending on October 30, 2023. |
Calculation
Agent: |
BofA Securities, Inc. (“BofAS”), an affiliate of BofA Finance. |
Selling
Agent: |
BofAS |
CUSIP: |
09709UZE1 |
Underlying
Return: |
With respect to each Underlying,

|
Least Performing
Underlying: |
The Underlying with the lowest Underlying Return. |
Events of Default
and Acceleration: |
If an Event of Default, as defined in the senior indenture relating
to the Notes and in the section entitled “Description of Debt
Securities—Events of Default and Rights of Acceleration” beginning
on page 22 of the accompanying prospectus, with respect to the
Notes occurs and is continuing, the amount payable to a holder of
the Notes upon any acceleration permitted under the senior
indenture will be equal to the amount described under the caption
“Redemption Amount” above, calculated as though the date of
acceleration were the Maturity Date of the Notes and as though the
Valuation Date were the third trading day prior to the date of
acceleration. We will also determine whether the final Contingent
Coupon Payment is payable based upon the prices of the Underlyings
on the deemed Valuation Date; any such final Contingent Coupon
Payment will be prorated by the calculation agent to reflect the
length of the final contingent payment period. In case of a default
in the payment of the Notes, whether at their maturity or upon
acceleration, the Notes will not bear a default interest rate. |
*Subject to change.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-3 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Observation Dates and Contingent Payment Dates
|
Observation
Dates* |
|
Contingent
Payment Dates |
|
|
April 25, 2022 |
|
April 28, 2022 |
|
|
July 25, 2022 |
|
July 28, 2022 |
|
|
October 25, 2022 |
|
October 28, 2022 |
|
|
January 25, 2023 |
|
January 30, 2023 |
|
|
April 25, 2023 |
|
April 28, 2023 |
|
|
July 25, 2023 |
|
July 28, 2023 |
|
|
October 25, 2023 |
|
October 30, 2023 |
|
|
January 25, 2024 (the “Valuation Date”) |
|
January 30, 2024 (the “Maturity Date”) |
|
* The Observation Dates are subject to postponement as set forth in
“Description of the Notes—Certain Terms of the Notes—Events
Relating to Observation Dates” beginning on page PS-22 of the
accompanying product supplement.
Any payments on the Notes depend on the credit risk of BofA
Finance, as Issuer, and BAC, as Guarantor, and on the performance
of the Underlyings. The economic terms of the Notes are based on
BAC’s internal funding rate, which is the rate it would pay to
borrow funds through the issuance of market-linked notes, and the
economic terms of certain related hedging arrangements BAC’s
affiliates enter into. BAC’s internal funding rate is typically
lower than the rate it would pay when it issues conventional fixed
or floating rate debt securities. This difference in funding rate,
as well as the underwriting discount, if any, and the hedging
related charges described below (see “Risk Factors” beginning on
page PS-8), will reduce the economic terms of the Notes to you and
the initial estimated value of the Notes. Due to these factors, the
public offering price you pay to purchase the Notes will be greater
than the initial estimated value of the Notes as of the pricing
date.
The initial estimated value range of the Notes is set forth on the
cover page of this pricing supplement. The final pricing supplement
will set forth the initial estimated value of the Notes as of the
pricing date. For more information about the initial estimated
value and the structuring of the Notes, see “Risk Factors”
beginning on page PS-8 and “Structuring the Notes” on page
PS-22.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-4 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Contingent Coupon Payment and Redemption Amount Determination
On each Contingent Payment
Date, you may receive a
Contingent Coupon Payment per
$1,000 in principal amount of Notes determined as
follows:

Assuming the Notes have not
been called,
on the Maturity Date, you will
receive a cash payment per $1,000 in principal amount of Notes
determined as follows:

All payments described above are subject to the credit risk of BofA
Finance, as issuer, and BAC, as guarantor.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-5 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Total Contingent Coupon Payment Examples
The table below illustrates the hypothetical total Contingent
Coupon Payments per $1,000 in principal amount of Notes over the
term of the Notes, based on the Contingent Coupon Payment of
$31.875, depending on how many Contingent Coupon Payments are
payable prior to an Optional Early Redemption or maturity.
Depending on the performance of the Underlyings, you may not
receive any Contingent Coupon Payments during the term of the
Notes.
|
Number of
Contingent Coupon Payments |
|
Total
Contingent Coupon Payments |
|
|
0 |
|
$0.00 |
|
|
2 |
|
$63.75 |
|
|
4 |
|
$127.50 |
|
|
6 |
|
$191.25 |
|
|
8 |
|
$255.00 |
|
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-6 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Hypothetical Payout Profile and Examples of Payments at
Maturity
Contingent Income Issuer
Callable Yield Notes Table
The following table is for purposes of illustration only. It
assumes the Notes have not been called prior to maturity and is
based on hypothetical values and shows hypothetical
returns on the Notes. The table illustrates the calculation of the
Redemption Amount and the return on the Notes based on a
hypothetical Starting Value of 100 for the Least Performing
Underlying, a hypothetical Coupon Barrier of 65 for the Least
Performing Underlying, a hypothetical Threshold Value of 65 for the
Least Performing Underlying, the Contingent Coupon Payment of
$31.875 per $1,000 in principal amount of Notes and a range of
hypothetical Ending Values of the Least Performing Underlying.
The actual amount you receive and the resulting return will
depend on the actual Starting Values, Coupon Barriers, Threshold
Values, Observation Values and Ending Values of the Underlyings,
whether the Notes are called prior to maturity, and whether you
hold the Notes to maturity. The following examples do not take
into account any tax consequences from investing in the Notes.
For recent actual values of the Underlyings, see “The Underlyings”
section below. The Ending Value of each Underlying will not include
any income generated by dividends or other distributions paid with
respect to shares or units of that Underlying or on the securities
included in that Underlying, as applicable. In addition, all
payments on the Notes are subject to Issuer and Guarantor credit
risk.
Ending Value of the Least
Performing Underlying
|
Underlying Return of the Least
Performing Underlying
|
Redemption Amount per Note
(including any final Contingent Coupon Payment)
|
Return on the
Notes(1)
|
160.00 |
60.00% |
$1,031.875 |
3.1875% |
150.00 |
50.00% |
$1,031.875 |
3.1875% |
140.00 |
40.00% |
$1,031.875 |
3.1875% |
130.00 |
30.00% |
$1,031.875 |
3.1875% |
120.00 |
20.00% |
$1,031.875 |
3.1875% |
110.00 |
10.00% |
$1,031.875 |
3.1875% |
105.00 |
5.00% |
$1,031.875 |
3.1875% |
102.00 |
2.00% |
$1,031.875 |
3.1875% |
100.00(2) |
0.00% |
$1,031.875 |
3.1875% |
90.00 |
-10.00% |
$1,031.875 |
3.1875% |
80.00 |
-20.00% |
$1,031.875 |
3.1875% |
70.00 |
-30.00% |
$1,031.875 |
3.1875% |
65.00(3) |
-35.00% |
$1,031.875 |
3.1875% |
64.99 |
-35.01% |
$649.900 |
-35.0100% |
50.00 |
-50.00% |
$500.000 |
-50.0000% |
0.00 |
-100.00% |
$0.000 |
-100.0000% |
(1) |
The
“Return on the Notes” is calculated based on the Redemption Amount
and potential final Contingent Coupon Payment, not including any
Contingent Coupon Payments paid prior to maturity. |
(2) |
The
hypothetical Starting Value of 100 used in the table above has been
chosen for illustrative purposes only and does not represent a
likely Starting Value of any Underlying. |
(3) |
This is
the hypothetical Coupon Barrier and Threshold Value of the Least
Performing Underlying. |
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-7 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Risk Factors
Your investment in the Notes entails significant risks, many of
which differ from those of a conventional debt security. Your
decision to purchase the Notes should be made only after carefully
considering the risks of an investment in the Notes, including
those discussed below, with your advisors in light of your
particular circumstances. The Notes are not an appropriate
investment for you if you are not knowledgeable about significant
elements of the Notes or financial matters in general. You should
carefully review the more detailed explanation of risks relating to
the Notes in the “Risk Factors” sections beginning on page PS-5 of
the accompanying product supplement, page S-5 of the accompanying
prospectus supplement and page 7 of the accompanying prospectus,
each as identified on page PS-27 below.
Structure-related Risks
|
● |
Your investment may result in a loss; there is no guaranteed
return of principal. There is no fixed principal repayment
amount on the Notes at maturity. If the Notes are not called prior
to maturity and the Ending Value of any Underlying is less
than its Threshold Value, at maturity, your investment will be
subject to 1:1 downside exposure to decreases in the value of the
Least Performing Underlying and you will lose 1% of the principal
amount for each 1% that the Ending Value of the Least Performing
Underlying is less than its Starting Value. In that case, you will
lose a significant portion or all of your investment in the
Notes. |
|
● |
Your return on the Notes is limited to the return
represented by the Contingent Coupon Payments, if any, over the
term of the Notes. Your return on the Notes is limited to the
Contingent Coupon Payments paid over the term of the Notes,
regardless of the extent to which the Observation Value or Ending
Value of any Underlying exceeds its Coupon Barrier or Starting
Value, as applicable. Similarly, the amount payable at maturity or
upon an Optional Early Redemption will never exceed the sum of the
principal amount and the applicable Contingent Coupon Payment,
regardless of the extent to which the Observation Value of any
Underlying exceeds its Starting Value. In contrast, a direct
investment in an Underlying or in the securities included in one or
more of the Underlyings would allow you to receive the benefit of
any appreciation in their prices. Any return on the Notes will not
reflect the return you would realize if you actually owned those
securities and received the dividends paid or distributions made on
them. |
|
● |
The Notes are subject to Optional Early Redemption, which
would limit your ability to receive the Contingent Coupon Payments
over the full term of the Notes. On each Call Date, at our
option, we may call your Notes in whole, but not in part. If the
Notes are called prior to the Maturity Date, you will be entitled
to receive the Early Redemption Amount. In this case, you will lose
the opportunity to continue to receive Contingent Coupon Payments
after the date of the Optional Early Redemption. If the Notes are
called prior to the Maturity Date, you may be unable to invest in
other securities with a similar level of risk that could provide a
return that is similar to the Notes. Even if we do not exercise our
option to call your Notes, our ability to do so may adversely
affect the market value of your Notes. It is our sole option
whether to call your Notes prior to maturity on any such Call Date
and we may or may not exercise this option for any reason. Because
of this Optional Early Redemption potential, the term of your Notes
could be anywhere between six and twenty-four months. |
|
● |
You may not receive any Contingent Coupon Payments. The
Notes do not provide for any regular fixed coupon payments.
Investors in the Notes will not necessarily receive any Contingent
Coupon Payments on the Notes. If the Observation Value of any
Underlying is less than its Coupon Barrier on an Observation Date,
you will not receive the Contingent Coupon Payment applicable to
that Observation Date. If the Observation Value of any Underlying
is less than its Coupon Barrier on all the Observation Dates during
the term of the Notes, you will not receive any Contingent Coupon
Payments during the term of the Notes, and will not receive a
positive return on the Notes. |
|
● |
Your return on the Notes may be less than the yield on a
conventional debt security of comparable maturity. Any return
that you receive on the Notes may be less than the return you would
earn if you purchased a conventional debt security with the same
Maturity Date. As a result, your investment in the Notes may not
reflect the full opportunity cost to you when you consider factors,
such as inflation, that affect the time value of money. In
addition, if interest rates increase during the term of the Notes,
the Contingent Coupon Payment (if any) may be less than the yield
on a conventional debt security of comparable maturity. |
|
● |
The Contingent Coupon Payment, Early Redemption Amount or
Redemption Amount, as applicable, will not reflect changes in the
prices of the Underlyings other than on the Observation Dates.
The prices of the Underlyings during the term of the Notes other
than on the Observation Dates will not affect payments on the
Notes. Notwithstanding the foregoing, investors should generally be
aware of the performance of the Underlyings while holding the
Notes, as the performance of the Underlyings may influence the
market value of the Notes. The calculation agent will determine
whether each Contingent Coupon Payment is payable and will
calculate the Early Redemption Amount or the Redemption Amount, as
applicable, by comparing only the Coupon Barrier or the Threshold
Value, as applicable, to the Observation Value or the Ending Value
for each Underlying. No other prices of the Underlyings will be
taken into account. As a result, if the Notes are not called prior
to maturity, and the Ending Value of the Least Performing
Underlying is less than its Threshold Value, you will receive less
than the principal amount at maturity even if the price of each
Underlying was always above its Threshold Value prior to the
Valuation Date. |
|
● |
Because the Notes are linked to the least performing (and
not the average performance) of the Underlyings, you may not
receive any return on the Notes and may lose a significant portion
or all of your investment in the Notes even if the Observation
Value or Ending Value of one Underlying is greater than or equal to
its Coupon Barrier or Threshold Value, as applicable. Your
Notes are linked to the least performing of the Underlyings, and a
change in the price of one Underlying may not correlate with
changes in the price of the other Underlying(s). The Notes are not
linked to a basket composed of the Underlyings, where the
depreciation in the price of one Underlying could be offset to some
extent by the appreciation in the price of the other Underlying(s).
In the case of the Notes, the individual performance of each
Underlying would not be combined, and the depreciation in the price
of one Underlying would not be offset by any appreciation in the
price of the other Underlying(s). Even if the Observation Value of
an Underlying is at or above its Coupon Barrier on an Observation
Date, you will not receive the Contingent Coupon Payment with
respect to that Observation Date if the Observation Value of
another Underlying is below its Coupon Barrier on that day. In
addition, even if the Ending Value of an Underlying is at or above
its Threshold Value, you will lose a significant portion or all of
your investment in the Notes if the Ending Value of the Least
Performing Underlying is below its Threshold Value. |
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-8 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
|
● |
Any payments on the Notes are subject to our credit risk and
the credit risk of the Guarantor, and any actual or perceived
changes in our or the Guarantor’s creditworthiness are expected to
affect the value of the Notes. The Notes are our senior
unsecured debt securities. Any payment on the Notes will be fully
and unconditionally guaranteed by the Guarantor. The Notes are not
guaranteed by any entity other than the Guarantor. As a result,
your receipt of the Early Redemption Amount or the Redemption
Amount at maturity, as applicable, will be dependent upon our
ability and the ability of the Guarantor to repay our respective
obligations under the Notes on the applicable Contingent Payment
Date or Call Date or the Maturity Date, regardless of the Ending
Value of the Least Performing Underlying as compared to its
Starting Value.
In addition, our credit ratings and the credit ratings of the
Guarantor are assessments by ratings agencies of our respective
abilities to pay our obligations. Consequently, our or the
Guarantor’s perceived creditworthiness and actual or anticipated
decreases in our or the Guarantor’s credit ratings or increases in
the spread between the yield on our respective securities and the
yield on U.S. Treasury securities (the “credit spread”) prior to
the Maturity Date may adversely affect the market value of the
Notes. However, because your return on the Notes depends upon
factors in addition to our ability and the ability of the Guarantor
to pay our respective obligations, such as the prices of the
Underlyings, an improvement in our or the Guarantor’s credit
ratings will not reduce the other investment risks related to the
Notes. |
|
● |
We are a finance subsidiary and, as such, have no
independent assets, operations, or revenues. We are a finance
subsidiary of the Guarantor, have no operations other than those
related to the issuance, administration and repayment of our debt
securities that are guaranteed by the Guarantor, and are dependent
upon the Guarantor and/or its other subsidiaries to meet our
obligations under the Notes in the ordinary course. Therefore, our
ability to make payments on the Notes may be limited. |
Valuation- and Market-related Risks
|
● |
The public offering price you pay for the Notes will exceed
their initial estimated value. The range of initial estimated
values of the Notes that is provided on the cover page of this
preliminary pricing supplement, and the initial estimated value as
of the pricing date that will be provided in the final pricing
supplement, are each estimates only, determined as of a particular
point in time by reference to our and our affiliates’ pricing
models. These pricing models consider certain assumptions and
variables, including our credit spreads and those of the Guarantor,
the Guarantor’s internal funding rate, mid-market terms on hedging
transactions, expectations on interest rates, dividends and
volatility, price-sensitivity analysis, and the expected term of
the Notes. These pricing models rely in part on certain
forecasts about future events, which may prove to be incorrect. If
you attempt to sell the Notes prior to maturity, their market value
may be lower than the price you paid for them and lower than their
initial estimated value. This is due to, among other things,
changes in the prices of the Underlyings, changes in the
Guarantor’s internal funding rate, and the inclusion in the public
offering price of the underwriting discount, if any, and the
hedging related charges, all as further described in “Structuring
the Notes” below. These factors, together with various credit,
market and economic factors over the term of the Notes, are
expected to reduce the price at which you may be able to sell the
Notes in any secondary market and will affect the value of the
Notes in complex and unpredictable ways. |
|
● |
The initial estimated value does not represent a minimum or
maximum price at which we, BAC, BofAS or any of our other
affiliates would be willing to purchase your Notes in any secondary
market (if any exists) at any time. The value of your Notes at
any time after issuance will vary based on many factors that cannot
be predicted with accuracy, including the performance of the
Underlyings, our and BAC’s creditworthiness and changes in market
conditions. |
|
● |
We cannot assure you that a trading market for your Notes
will ever develop or be maintained. We will not list the Notes
on any securities exchange. We cannot predict how the Notes will
trade in any secondary market or whether that market will be liquid
or illiquid. |
Conflict-related Risks
|
● |
Trading and hedging activities by us, the Guarantor and any
of our other affiliates, including BofAS, may create conflicts of
interest with you and may affect your return on the Notes and their
market value. We, the Guarantor or one or more of our other
affiliates, including BofAS, may buy or sell shares or units of the
Underlyings or the securities held by or included in the
Underlyings, or futures or options contracts or exchange traded
instruments on the Underlyings or those securities, or other
instruments whose value is derived from the Underlyings or those
securities. While we, the Guarantor or one or more of our other
affiliates, including BofAS, may from time to time own shares or
units of the Underlyings or the securities included in the
Underlyings, except to the extent that BAC’s common stock may be
included in the Underlyings, we, the Guarantor and our other
affiliates, including BofAS, do not control any company included in
the Underlyings, and have not verified any disclosure made by any
other company. We, the Guarantor or one or more of our other
affiliates, including BofAS, may execute such purchases or sales
for our own or their own accounts, for business reasons, or in
connection with hedging our obligations under the Notes. These
transactions may present a conflict of interest between your
interest in the Notes and the interests we, the Guarantor and our
other affiliates, including BofAS, may have in our or their
proprietary accounts, in facilitating transactions, including block
trades, for our or their other customers, and in accounts under our
or their management. These transactions may adversely affect the
prices of the Underlyings in a manner that could be adverse to your
investment in the Notes. On or before the pricing date, any
purchases or sales by us, the Guarantor or our other affiliates,
including BofAS or others on our or their behalf (including those
for the purpose of hedging some or all of our anticipated exposure
in connection with the Notes), may affect the prices of the
Underlyings. Consequently, the prices of the Underlyings may change
subsequent to the pricing date, which may adversely affect the
market value of the Notes.
We, the Guarantor or one or more of our other affiliates, including
BofAS, also expect to engage in hedging activities that could
affect the prices of the Underlyings on the pricing date. In
addition, these hedging activities, including the unwinding of a
hedge, may decrease the market value of your Notes prior to
maturity, and may affect the amounts to be paid on the Notes. We,
the Guarantor or one or more of our other affiliates, including
BofAS, may purchase or otherwise acquire a long or short position
in the Notes and may hold or resell the Notes. For example, BofAS
may enter into these transactions in connection with any market
making activities in which it engages. We cannot assure you that
these activities will not adversely affect the prices of the
Underlyings, the market value of your Notes prior to maturity or
the amounts payable on the Notes. |
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-9 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
|
● |
There may be potential conflicts of interest involving the
calculation agent, which is an affiliate of ours. We have the
right to appoint and remove the calculation agent. One of our
affiliates will be the calculation agent for the Notes and, as
such, will make a variety of determinations relating to the Notes,
including the amounts that will be paid on the Notes. Under some
circumstances, these duties could result in a conflict of interest
between its status as our affiliate and its responsibilities as
calculation agent. |
Underlying-related Risks
|
● |
The anti-dilution adjustments will be limited. The
calculation agent may adjust the Price Multiplier of an Underlying
and other terms of the Notes to reflect certain actions by an
Underlying, as described in the section “Description of the
Notes—Anti-Dilution and Discontinuance Adjustments Relating to
ETFs” in the accompanying product supplement. The calculation agent
will not be required to make an adjustment for every event that may
affect an Underlying and will have broad discretion to determine
whether and to what extent an adjustment is required. |
|
● |
The sponsor or investment advisor of an Underlying may
adjust that Underlying in a way that affects its prices, and the
sponsor or investment advisor has no obligation to consider your
interests. The sponsor or investment advisor of an Underlying
can add, delete, or substitute the components included in that
Underlying or make other methodological changes that could change
its price. Any of these actions could adversely affect the value of
your Notes. |
|
● |
The stocks held by the XBI, the KRE or the XLI are
concentrated in three sectors. The Underlyings hold securities
issued by companies in the biotechnology sector, the regional
banking sector or the industrial sector, respectively. As a result,
the stocks that will determine the performance of the Notes are
concentrated in three sectors. Although an investment in the Notes
will not give holders any ownership or other direct interests in
the securities held by the Underlyings, the return on an investment
in the Notes will be subject to certain risks associated with a
direct equity investment in companies in these sectors.
Accordingly, by investing in the Notes, you will not benefit from
the diversification which could result from an investment linked to
companies that operate in multiple sectors. |
|
● |
The Notes are subject to risks associated with the banking
industry. All of the stocks held by the KRE are issued by
companies in the banking industry. The performance of companies in
the banking industry are influenced by many complex and
unpredictable factors, including industry competition, interest
rates, geopolitical events, the ability of borrowers to repay
loans, government regulation, and supply and demand for the
products and services offered by such companies. Any adverse
development in the banking industry may have a material adverse
effect on the stocks held by the KRE, and as a result, on the value
of the Notes. The Notes may be subject to greater volatility and be
more adversely affected by a single positive or negative economic,
political or regulatory occurrence affecting this industry than a
different investment linked to securities of a more broadly
diversified group of issuers. |
|
● |
Adverse conditions in the industrial sector may reduce your
return on the Notes. All of the stocks held by the XLI are
issued by companies whose primary lines of business are directly
associated with the industrial sector. The profitability of these
companies is largely affected by supply and demand for their
product or service and for industrial sector products in general.
Government regulation, world events, exchange rates and economic
conditions, technological developments and general civil
liabilities will likewise affect the performance of these
companies. Aerospace and defense companies, a component of the
industrial sector, can be significantly affected by government
spending policies. As a result of these factors, the value of the
Notes may be subject to greater volatility and be more adversely
affected by economic, political, or regulatory events relating to
the industrial services sector. |
|
● |
Adverse conditions in the biotechnology sector may reduce
your return on the Notes. All of the stocks held by the XBI are
issued by companies whose primary lines of business are directly
associated with the biotechnology sector. The profitability of
these companies is largely dependent on, among other things, demand
for the companies’ products, regulatory influences on the
biotechnology market (including healthcare reform and receipt of
regulatory approvals and compliance with complex regulatory
requirements), pricing and reimbursement from third party payors,
continued innovation and successful development of new products,
talent attraction and retention, maintaining intellectual property
rights and industry competition. Any adverse developments affecting
the biotechnology sector could adversely affect the price of the
XBI and, in turn, the value of the Notes. |
|
● |
The performance of an Underlying may not correlate with the
performance of its underlying index as well as the net asset value
per share or unit of the Underlying, especially during periods of
market volatility. The performance of an Underlying and that of
its underlying index generally will vary due to, for example,
transaction costs, management fees, certain corporate actions, and
timing variances. Moreover, it is also possible that the
performance of an Underlying may not fully replicate or may, in
certain circumstances, diverge significantly from the performance
of its underlying index. This could be due to, for example, the
Underlying not holding all or substantially all of the underlying
assets included in its underlying index and/or holding assets that
are not included in its underlying index, the temporary
unavailability of certain securities in the secondary market, the
performance of any derivative instruments held by the Underlying,
differences in trading hours between the Underlying (or the
underlying assets held by the Underlying) and its underlying index,
or other circumstances. This variation in performance is called the
“tracking error,” and, at times, the tracking error may be
significant. In addition, because the shares or units of each
Underlying are traded on a securities exchange and are subject to
market supply and investor demand, the market price of one share or
unit of the Underlying may differ from its net asset value per
share or unit; shares or units of the Underlying may trade at,
above, or below its net asset value per share or unit. During
periods of market volatility, securities held by an Underlying may
be unavailable in the secondary market, market participants may be
unable to calculate accurately the net asset value per share or
unit of the Underlying and the liquidity of the Underlying may be
adversely affected. Market volatility may also disrupt the ability
of market participants to trade shares or units of the Underlying.
Further, market volatility may adversely affect, sometimes
materially, the prices at which market participants are willing to
buy and sell shares or units of the Underlying. As a result, under
these circumstances, the market value of shares or units of the
Underlying may vary substantially from the net asset value per
share or unit of the Underlying. |
Tax-related Risks
|
● |
The U.S. federal income tax consequences of an investment in
the Notes are uncertain, and may be adverse to a holder of the
Notes. No statutory, judicial, or administrative authority
directly addresses the characterization of the Notes or securities
similar to the Notes for U.S. |
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-10 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
federal income tax purposes. As a result, significant aspects of
the U.S. federal income tax consequences of an investment in the
Notes are not certain. Under the terms of the Notes, you will have
agreed with us to treat the Notes as contingent income-bearing
single financial contracts, as described below under “U.S. Federal
Income Tax Summary—General.” If the Internal Revenue Service (the
“IRS”) were successful in asserting an alternative characterization
for the Notes, the timing and character of income, gain or loss
with respect to the Notes may differ. No ruling will be requested
from the IRS with respect to the Notes and no assurance can be
given that the IRS will agree with the statements made in the
section entitled “U.S. Federal Income Tax Summary.” You are
urged to consult with your own tax advisor regarding all aspects of
the U.S. federal income tax consequences of investing in the
Notes.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-11 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
The
Underlyings
All disclosures contained in this pricing supplement regarding the
Underlyings, including, without limitation, their make-up, method
of calculation, and changes in their components, have been derived
from publicly available sources. The information reflects the
policies of, and is subject to change by, the investment advisor of
the XLI, the investment advisor of the XBI, and the investment
advisor of the KRE (collectively, the “Investment Advisors”). The
Investment Advisors, which license the copyright and all other
rights to the respective Underlyings, have no obligation to
continue to publish, and may discontinue publication of, the
Underlyings. The consequences of any Investment Advisor
discontinuing publication of the applicable Underlying are
discussed in “Description of the Notes — Anti-Dilution and
Discontinuance Adjustments Relating to ETFs — Discontinuance of or
Material Change to an ETF” in the accompanying product supplement.
None of us, the Guarantor, the calculation agent, or BofAS accepts
any responsibility for the calculation, maintenance or publication
of any Underlying or any successor underlying. None of us, the
Guarantor, BofAS or any of our other affiliates makes any
representation to you as to the future performance of the
Underlyings. You should make your own investigation into the
Underlyings.
The Industrial Select Sector
SPDR®
Fund
The shares of the XLI are issued by Select Sector SPDR®
Trust, a registered investment company. The XLI seeks investment
results that correspond generally to the price and yield
performance, before fees and expenses, of the Industrial Select
Sector Index, its underlying index. The Industrial Select Sector
Index measures the performance of the industrial sector of the U.S.
equity market. The XLI is composed of equity securities of
companies in aerospace and defense, industrial conglomerates,
marine, transportation infrastructure and machinery industries. The
XLI trades on the NYSE Arca under the ticker symbol “XLI.”
Investment Approach
The XLI utilizes a “passive” or “indexing” investment approach in
attempting to track the performance of the Industrial Select Sector
Index. The XLI will invest in substantially all of the securities
which comprise the Industrial Select Sector Index. The XLI will
normally invest at least 95% of its total assets in common stocks
that comprise the Industrial Select Sector Index.
Investment Objective and Strategy
The XLI seeks to provide investment results that correspond
generally to the price and yield performance, before fees and
expenses, of the Industrial Select Sector Index. The investment
manager of the XLI uses a replication strategy to try to achieve
the XLI’s investment objective, which means that the XLI generally
invests in substantially all of the securities represented in the
Industrial Select Sector Index in approximately the same
proportions as the Industrial Select Sector Index. Under normal
market conditions, the XLI generally invests at least 95% of its
total assets in the securities comprising the Industrial Select
Sector Index. In certain situations or market conditions, the XLI
may temporarily depart from its normal investment policies and
strategies provided that the alternative is consistent with the
XLI’s investment objective and is in the best interest of the XLI.
For example, if the XLI is unable to invest directly in a component
security or if a derivative investment may provide higher liquidity
than other types of investments, it may make larger than normal
investments in derivatives to maintain exposure to the Industrial
Select Sector Index that it tracks. Consequently, under such
circumstances, the XLI may invest in a different mix of investments
than it would under normal circumstances. The XLI will provide
shareholders with at least 60 days notice prior to any material
change in its investment policies. The XLI is managed with a
passive investment strategy, attempting to track the performance of
an unmanaged index of securities. This differs from an actively
managed underlying, which typically seeks to outperform a benchmark
index.
Notwithstanding the XLI’s investment objective, the return on your
Notes will not reflect any dividends paid on shares of the XLI, on
the securities purchased by the XLI or on the securities that
comprise the Industrial Select Sector Index.
The Select Sector Indices
The underlying index of the XLI is part of the Select Sector
Indices. The Select Sector Indices are sub-indices of the S&P
500® Index (“SPX”). Each stock in the SPX is allocated
to at least one Select Sector Index, and the combined companies of
the eleven Select Sector Indices represent all of the companies in
the SPX. The industry indices are sub-categories within each Select
Sector Index and represent a specific industry segment of the
overall Select Sector Index. The eleven Select Sector Indices seek
to represent the eleven SPX sectors. The index compilation agent
for these indices (the “Index Compilation Agent”) determines the
composition of the Select Sector Indices based on S&P’s sector
classification methodology. (Sector designations are determined by
the index sponsor using criteria it has selected or developed.
Index sponsors may use very different standards for determining
sector designations. In addition, many companies operate in a
number of sectors, but are listed in only one sector and the basis
on which that sector is selected may also differ. As a result,
sector comparisons between indices with different index sponsors
may reflect differences in methodology as well as actual
differences in the sector composition of the indices.
Each Select Sector Index was developed and is maintained in
accordance with the following criteria:
|
● |
Each of the component stocks in a
Select Sector Index (the “Component Stocks”) is a constituent
company of the SPX. |
|
● |
The eleven Select Sector Indices
together will include all of the companies represented in the SPX
and each of the stocks in the SPX will be allocated to at least one
of the Select Sector Indices. |
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-12 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
|
● |
The Index Compilation Agent
assigns each constituent stock of the SPX to a Select Sector Index.
The Index Compilation Agent assigns a company’s stock to a
particular Select Sector Index based on S&P Dow Jones Indices’s
sector classification methodology as set forth in its Global
Industry Classification Standard. |
|
● |
Each Select Sector Index is
calculated by S&P Dow Jones Indices using a modified “market
capitalization” methodology. This design ensures that each of the
component stocks within a Select Sector Index is represented in a
proportion consistent with its percentage with respect to the total
market capitalization of that Select Sector Index. |
|
● |
For reweighting purposes, each
Select Sector Index is rebalanced quarterly after the close of
business on the second to last calculation day of March, June,
September and December using the following procedures: (1) The
rebalancing reference date is two business days prior to the last
calculation day of each quarter; and (2) With prices reflected on
the rebalancing reference date, and membership, shares outstanding,
additional weight factor (capping factor) and investable weight
factors (as described in the section “Computation of the S&P
500 Index®” below) as of the rebalancing
effective date, each company is weighted using the modified market
capitalization methodology. Modifications are made as defined
below. |
(i) |
The indices are first evaluated to ensure none of the indices
breach the maximum allowable limits defined in rules (ii) and (v)
below. If any of the allowable limits are breached, the component
stocks are reweighted based on their float-adjusted market
capitalization weights.
|
(ii) |
If any component stock has a weight greater than 24%, that
component stock has its float-adjusted market capitalization weight
capped at 23%. The 23% weight cap creates a 2% buffer to ensure
that no component stock exceeds 25% as of the quarter-end
diversification requirement date.
|
(iii) |
All excess weight is equally redistributed to all uncapped
component stocks within the relevant Select Sector Index.
|
(iv) |
After this redistribution, if the float-adjusted market
capitalization weight of any other component stock(s) then breaches
23%, the process is repeated iteratively until no component stock
breaches the 23% weight cap.
|
(v) |
The sum of the component stocks with weight greater than 4.8%
cannot exceed 50% of the total index weight. These caps are set to
allow for a buffer below the 5% limit.
|
(vi) |
If the rule in step (v) is breached, all the component stocks are
ranked in descending order of their float-adjusted market
capitalization weights and the first component stock that causes
the 50% limit to be breached has its weight reduced to 4.6%.
|
(vii) |
This excess weight is equally redistributed to all component stocks
with weights below 4.6%. This process is repeated iteratively until
step (v) is satisfied.
|
(viii) |
Index share amounts are assigned to each component stock to arrive
at the weights calculated above. Since index shares are assigned
based on prices one business day prior to rebalancing, the actual
weight of each component stock at the rebalancing differs somewhat
from these weights due to market movements.
|
|
● |
Each Select Sector Index is
calculated using the same methodology utilized by S&P Dow Jones
Indices in calculating the SPX, using a base-weighted aggregate
methodology. The daily calculation of each Select Sector Index is
computed by dividing the total market value of the companies
in the Select Sector Index by a number called the index
divisor. |
|
● |
The Index Compilation Agent at any
time may determine that a Component Stock which has been assigned
to one Select Sector Index has undergone such a transformation in
the composition of its business, and should be removed from that
Select Sector Index and assigned to a different Select Sector
Index. In the event that the Index Compilation Agent notifies
S&P Dow Jones Indices that a Component Stock’s Select Sector
Index assignment should be changed, S&P Dow Jones Indices will
disseminate notice of the change following its standard procedure
for announcing index changes and will implement the change in the
affected Select Sector Indices on a date no less than one week
after the initial dissemination of information on the sector change
to the maximum extent practicable. It is not anticipated that
Component Stocks will change sectors frequently. |
|
● |
Component Stocks removed from and
added to the SPX will be deleted from and added to the appropriate
Select Sector Index on the same schedule used by S&P Dow Jones
Indices for additions and deletions from the SPX insofar as
practicable. |
The S&P 500® Index
The SPX includes a representative sample of 500 companies in
leading industries of the U.S. economy. The SPX is intended to
provide an indication of the pattern of common stock price
movement. The calculation of the level of the SPX is based on the
relative value of the aggregate market value of
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-13 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
the common stocks of 500 companies as of a particular time compared
to the aggregate average market value of the common stocks of 500
similar companies during the base period of the years 1941 through
1943.
The SPX includes companies from eleven main groups: Communication
Services; Consumer Discretionary; Consumer Staples; Energy;
Financials; Health Care; Industrials; Information Technology; Real
Estate; Materials; and Utilities. S&P Dow Jones Indices LLC
(“SPDJI”), the sponsor of the SPX, may from time to time, in its
sole discretion, add companies to, or delete companies from, the
SPX to achieve the objectives stated above.
Company additions to the SPX must have an unadjusted company market
capitalization of $8.2 billion or more (an increase from the
previous requirement of an unadjusted company market capitalization
of $6.1 billion or more).
SPDJI calculates the SPX by reference to the prices of the
constituent stocks of the SPX without taking account of the value
of dividends paid on those stocks. As a result, the return on the
Notes will not reflect the return you would realize if you actually
owned the SPX constituent stocks and received the dividends paid on
those stocks.
Computation of the SPX
While SPDJI currently employs the following methodology to
calculate the SPX, no assurance can be given that SPDJI will not
modify or change this methodology in a manner that may affect
payments on the Notes.
Historically, the market value of any component stock of the SPX
was calculated as the product of the market price per share and the
number of then outstanding shares of such component stock. In March
2005, SPDJI began shifting the SPX halfway from a market
capitalization weighted formula to a float-adjusted formula, before
moving the SPX to full float adjustment on September 16, 2005.
SPDJI’s criteria for selecting stocks for the SPX did not change
with the shift to float adjustment. However, the adjustment affects
each company’s weight in the SPX.
Under float adjustment, the share counts used in calculating the
SPX reflect only those shares that are available to investors, not
all of a company’s outstanding shares. Float adjustment excludes
shares that are closely held by control groups, other publicly
traded companies or government agencies.
In September 2012, all shareholdings representing more than 5% of a
stock’s outstanding shares, other than holdings by “block owners,”
were removed from the float for purposes of calculating the SPX.
Generally, these “control holders” will include officers and
directors, private equity, venture capital and special equity
firms, other publicly traded companies that hold shares for
control, strategic partners, holders of restricted shares, ESOPs,
employee and family trusts, foundations associated with the
company, holders of unlisted share classes of stock, government
entities at all levels (other than government retirement/pension
funds) and any individual person who controls a 5% or greater stake
in a company as reported in regulatory filings. However, holdings
by block owners, such as depositary banks, pension funds, mutual
funds and ETF providers, 401(k) plans of the company, government
retirement/pension funds, investment funds of insurance companies,
asset managers and investment funds, independent foundations and
savings and investment plans, will ordinarily be considered part of
the float.
Treasury stock, stock options, restricted shares, equity
participation units, warrants, preferred stock, convertible stock,
and rights are not part of the float. Shares held in a trust to
allow investors in countries outside the country of domicile, such
as depositary shares and Canadian exchangeable shares, are normally
part of the float unless those shares form a control block. If a
company has multiple classes of stock outstanding, shares in an
unlisted or non-traded class are treated as a control block.
For each stock, an investable weight factor (“IWF”) is calculated
by dividing the available float shares by the total shares
outstanding. Available float shares are defined as the total shares
outstanding less shares held by control holders. This calculation
is subject to a 5% minimum threshold for control blocks. For
example, if a company’s officers and directors hold 3% of the
company’s shares, and no other control group holds 5% of the
company’s shares, SPDJI would assign that company an IWF of 1.00,
as no control group meets the 5% threshold. However, if a company’s
officers and directors hold 3% of the company’s shares and another
control group holds 20% of the company’s shares, SPDJI would assign
an IWF of 0.77, reflecting the fact that 23% of the company’s
outstanding shares are considered to be held for control. As of
July 31, 2017, companies with multiple share class lines are no
longer eligible for inclusion in the SPX. Constituents of the SPX
prior to July 31, 2017 with multiple share class lines will be
grandfathered in and continue to be included in the SPX. If a
constituent company of the SPX reorganizes into a multiple share
class line structure, that company will remain in the SPX at the
discretion of the S&P Index Committee in order to minimize
turnover.
The SPX is calculated using a base-weighted aggregate methodology.
The level of the SPX reflects the total market value of all
component stocks relative to the base period of the years 1941
through 1943. An indexed number is used to represent the results of
this calculation in order to make the level easier to work with and
track over time. The actual total market value of the component
stocks during the base period of the years 1941 through 1943 has
been set to an indexed level of 10. This is often indicated by the
notation 1941- 43 = 10. In practice, the daily calculation of the
SPX is computed by dividing the total market value of the component
stocks by the “index divisor.” By itself, the index divisor is an
arbitrary number. However, in the context of the calculation of the
SPX, it serves as a link to the original base period level of the
SPX. The index divisor keeps the SPX comparable over time and is
the manipulation point for all adjustments to the SPX, which is
index maintenance.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-14 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Index Maintenance
Index maintenance includes monitoring and completing the
adjustments for company additions and deletions, share changes,
stock splits, stock dividends, and stock price adjustments due to
company restructuring or spinoffs. Some corporate actions, such as
stock splits and stock dividends, require changes in the common
shares outstanding and the stock prices of the companies in the
SPX, and do not require index divisor adjustments.
To prevent the level of the SPX from changing due to corporate
actions, corporate actions which affect the total market value of
the SPX require an index divisor adjustment. By adjusting the index
divisor for the change in market value, the level of the SPX
remains constant and does not reflect the corporate actions of
individual companies in the SPX. Index divisor adjustments are made
after the close of trading and after the calculation of the SPX
closing level.
Changes in a company’s shares outstanding of 5.00% or more due to
mergers, acquisitions, public offerings, tender offers, Dutch
auctions, or exchange offers are made as soon as reasonably
possible. Share changes due to mergers or acquisitions of publicly
held companies that trade on a major exchange are implemented when
the transaction occurs, even if both of the companies are not in
the same headline index, and regardless of the size of the change.
All other changes of 5.00% or more (due to, for example, company
stock repurchases, private placements, redemptions, exercise of
options, warrants, conversion of preferred stock, notes, debt,
equity participation units, at-the-market offerings, or other
recapitalizations) are made weekly and are announced on Fridays for
implementation after the close of trading on the following Friday.
Changes of less than 5.00% are accumulated and made quarterly on
the third Friday of March, June, September, and December, and are
usually announced two to five days prior.
If a change in a company’s shares outstanding of 5.00% or more
causes a company’s IWF to change by five percentage points or more,
the IWF is updated at the same time as the share change. IWF
changes resulting from partial tender offers are considered on a
case by case basis.
Historical Performance of the XLI
The following graph sets forth the daily historical performance of
the XLI in the period from January 3, 2017 through January 18,
2022. We obtained this historical data from Bloomberg L.P. We have
not independently verified the accuracy or completeness of the
information obtained from Bloomberg L.P. The horizontal line in the
graph represents the XLI’s hypothetical Coupon Barrier and
Threshold Value of $68.01 (rounded to two decimal places), which is
65% of the XLI’s hypothetical Starting Value of $104.63, which was
its Closing Market Price on January 18, 2022. The actual Starting
Value, Coupon Barrier and Threshold Value will be determined on the
pricing date.

This historical data on the XLI is not necessarily indicative of
the future performance of the XLI or what the value of the Notes
may be. Any historical upward or downward trend in the Closing
Market Price of the XLI during any period set forth above is not an
indication that the Closing Market Price of the XLI is more or less
likely to increase or decrease at any time over the term of the
Notes.
Before investing in the Notes, you should consult publicly
available sources for the Closing Market Prices and trading pattern
of the XLI.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-15 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
The SPDR®
S&P® Biotech ETF
The XBI seeks to provide investment results that correspond
generally to the price and yield performance, before fees and
expenses, of the S&P®
Biotechnology Select Industry® Index
(the “underlying index”). The underlying index represents the
biotechnology sub-industry portion of the Standard & Poor’s
(“S&P”) Total Market Index (“S&P TMI”), an index that
measures the performance of the U.S. equity market. The XBI is
composed of companies that are in the biotechnology sector. The XBI
trades on NYSE Arca under the ticker symbol “XBI.”
The XBI utilizes a “replication” investment approach in attempting
to track the performance of its underlying index. The XBI typically
invests in substantially all of the securities which comprise the
underlying index in approximately the same proportions as the
underlying index. The XBI will normally invest at least 80% of its
total assets in the common stocks that comprise the underlying
index.
The
S&P® Biotechnology Select Industry® Index
This underlying index is an equal-weighted index that is designed
to measure the performance of the biotechnology sub-industry
portion of the S&P TMI. The S&P TMI includes all U.S.
common equities listed on the New York Stock Exchange (the “NYSE”)
(including NYSE Arca), the NYSE American, the Nasdaq Global Select
Market, and the Nasdaq Capital Market. Each of the component stocks
in the underlying index is a constituent company within the
biotechnology sub-industry portion of the S&P TMI.
To be eligible for inclusion in the underlying index, companies
must be in the S&P TMI and must be included in the relevant
Global Industry Classification Standard (GICS) sub-industry. The
GICS was developed to establish a global standard for categorizing
companies into sectors and industries. In addition to the above,
companies must satisfy one of the two following combined size and
liquidity criteria:
|
● |
float-adjusted market
capitalization above US$500 million and float-adjusted liquidity
ratio above 90%; or |
|
● |
float-adjusted market
capitalization above US$400 million and float-adjusted liquidity
ratio above 150%. |
All U.S. companies satisfying these requirements are included in
the underlying index. The total number of companies in the
underlying index should be at least 35. If there are fewer than 35
stocks, stocks from a supplementary list of highly correlated
sub-industries that meet the market capitalization and liquidity
thresholds above are included in order of their float-adjusted
market capitalization to reach 35 constituents. Minimum market
capitalization requirements may be relaxed to ensure there are at
least 22 companies in the underlying index as of each rebalancing
effective date.
Eligibility factors include:
|
● |
Market Capitalization:
Float-adjusted market capitalization should be at least US$400
million for inclusion in the underlying index. Existing index
components must have a float-adjusted market capitalization of
US$300 million to remain in the underlying index at each
rebalancing. |
|
● |
Liquidity: The liquidity
measurement used is a liquidity ratio, defined as dollar value
traded over the previous 12-months divided by the float-adjusted
market capitalization as of the underlying index rebalancing
reference date. Stocks having a float-adjusted market
capitalization above US$500 million must have a liquidity ratio
greater than 90% to be eligible for addition to the underlying
index. Stocks having a float-adjusted market capitalization between
US$400 and US$500 million must have a liquidity ratio greater than
150% to be eligible for addition to the underlying index. Existing
index constituents must have a liquidity ratio greater than 50% to
remain in the underlying index at the quarterly rebalancing. The
length of time to evaluate liquidity is reduced to the available
trading period for IPOs or spin-offs that do not have 12 months of
trading history. |
|
● |
Takeover Restrictions: At the
discretion of S&P, constituents with shareholder ownership
restrictions defined in company bylaws may be deemed ineligible for
inclusion in the underlying index. Ownership restrictions
preventing entities from replicating the index weight of a company
may be excluded from the eligible universe or removed from the
underlying index. |
|
● |
Turnover: S&P believes turnover
in index membership should be avoided when possible. At times, a
company may appear to temporarily violate one or more of the
addition criteria. However, the addition criteria are for addition
to the underlying index, not for continued membership. As a result,
an index constituent that appears to violate the criteria for
addition to the underlying index will not be deleted unless ongoing
conditions warrant a change in the composition of the underlying
index. |
Computation of the Underlying Index
The underlying index is calculated as the underlying index market
value divided by the divisor. In an equal-weighted index like the
underlying index, the market capitalization of each stock used in
the calculation of the index market value is redefined so that each
stock has an equal weight in the index on each rebalancing date.
The adjusted market capitalization for each stock in the index is
calculated as the product of the stock price, the number of shares
outstanding, the stock’s float factor and the adjustment
factor.
A stock’s float factor refers to the number of shares outstanding
that are available to investors. S&P indices exclude shares
closely held by control groups from the underlying index
calculation because such shares are not available to investors. For
each stock, S&P calculates an Investable Weight Factor (IWF)
which is the percentage of total shares outstanding that are
included in the underlying index calculation.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-16 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
The adjustment factor for each stock is assigned at each
rebalancing date and is calculated by dividing a specific constant
set for the purpose of deriving the adjustment factor (often
referred to as modified index shares) by the number of stocks in
the underlying index multiplied by the float adjusted market value
of such stock on such rebalancing date.
Adjustments are also made to ensure that no stock in the underlying
index will have a weight that exceeds the value that can be traded
in a single day for a theoretical portfolio of $2 billion.
Theoretical portfolio values are reviewed annually and any updates
are made at the discretion of the underlying index committee, as
defined below. The maximum basket liquidity weight for each stock
in the underlying index will be calculated using the ratio of its
three-month median daily value traded to the theoretical portfolio
value of $2 billion. Each stock’s weight in the underlying index is
then compared to its maximum basket liquidity weight and is set to
the lesser of (1) its maximum basket liquidity weight or (2) its
initial equal weight. All excess weight is redistributed across the
underlying index to the uncapped stocks. If necessary, a final
adjustment is made to ensure that no stock in the underlying index
has a weight greater than 4.5%. No further adjustments are made if
the latter step would force the weight of those stocks limited to
their maximum basket liquidity weight to exceed that weight. If the
underlying index contains exactly 22 stocks as of the rebalancing
effective date, the underlying index will be equally weighted
without basket liquidity constraints.
If a company has more than one share class line in the S&P
Total Market Index, such company will be represented once by the
designated listing (generally the share class with both (i) the
highest one-year trading liquidity as defined by median daily value
traded and (ii) the largest float-adjusted market capitalization).
S&P reviews designated listings on an annual basis and any
changes are implemented after the close of the third Friday in
September. The last trading day in July is used as the reference
date for the liquidity and market capitalization data in such
determination. Once a listed share class line is added to the
underlying index, it may be retained in the underlying index even
though it may appear to violate certain constituent addition
criteria. For companies that issue a second publicly traded share
class to underlying index share class holders, the newly issued
share class line will be considered for inclusion if the event is
mandatory and the market capitalization of the distributed class is
not considered to be de minimis.
The underlying index is calculated by using the divisor methodology
used in all S&P equity indices. The initial divisor was set to
have a base value of 1,000 on June 20, 2003. The underlying index
level is the underlying index market value divided by the
underlying index divisor. In order to maintain underlying index
series continuity, it is also necessary to adjust the divisor at
each rebalancing. Therefore, the divisor (after rebalancing) equals
the underlying index market value (after rebalancing) divided by
the underlying index value before rebalancing. The divisor keeps
the underlying index comparable over time and is one manipulation
point for adjustments to the underlying index, which we refer to as
maintenance of the underlying index.
Historical Performance of the XBI
The following graph sets forth the daily historical performance of
the XBI in the period from January 3, 2017 through January 18,
2022. We obtained this historical data from Bloomberg L.P. We have
not independently verified the accuracy or completeness of the
information obtained from Bloomberg L.P. The horizontal line in the
graph represents the XBI’s hypothetical Coupon Barrier and
Threshold Value of $61.44 (rounded to two decimal places), which is
65% of the XBI’s hypothetical Starting Value of $94.52, which was
its Closing Market Price on January 18, 2022. The actual Starting
Value, Coupon Barrier and Threshold Value will be determined on the
pricing date.

This historical data on the XBI is not necessarily indicative of
the future performance of the XBI or what the value of the Notes
may be. Any historical upward or downward trend in the Closing
Market Price of the XBI during any period set forth above is not an
indication that the Closing Market Price of the XBI is more or less
likely to increase or decrease at any time over the term of the
Notes.
Before investing in the Notes, you should consult publicly
available sources for the Closing Market Prices and trading pattern
of the XBI.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-17 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
The SPDR®
S&P® Regional Banking ETF
The KRE seeks to provide investment results that correspond
generally to the price and yield performance, before fees and
expenses, of the S&P Regional Banks Select Industry Index (the
“Underlying Index”). The Underlying Index represents the regional
banks industry portion of the S&P® Total
Market Index (“S&P TMI”), an index that measures the
performance of the U.S. equity market. The KRE is composed of
companies that are regional banks.
The KRE utilizes a “replication” investment approach in attempting
to track the performance of the Underlying Index. The KRE typically
invests in substantially all of the securities which comprise the
Underlying Index in approximately the same proportions as the
Underlying Index. The KRE will normally invest at least 80% of its
total assets in the common stocks that comprise the Underlying
Index. The returns of the KRE may be affected by certain management
fees and other expenses, which are detailed in its prospectus.
The S&P Regional Banks Select Industry Index
This Underlying Index is an equal-weighted index that is designed
to measure the performance of the regional banks portion of the
S&P TMI. The S&P TMI includes all U.S. common equities
listed on the New York Stock Exchange (including NYSE Arca), the
NYSE MKT, the NASDAQ Global Select Market, and the NASDAQ Capital
Market. Each of the component stocks in the Underlying Index is a
constituent company within the regional banks industry portion of
the S&P TMI.
To be eligible for inclusion in the Underlying Index, companies
must be in the S&P TMI and must be included in the relevant
Global Industry Classification Standard (GICS) industry. The GICS
was developed to establish a global standard for categorizing
companies into sectors and industries. In addition to the above,
companies must satisfy one of the two following combined size and
liquidity criteria:
|
● |
float-adjusted market capitalization above US$500 million and
float-adjusted liquidity ratio above 90%; or |
|
● |
float-adjusted market capitalization above US$400 million and
float-adjusted liquidity ratio above 150%. |
All U.S. companies satisfying these requirements are included in
the Underlying Index. The total number of companies in the
Underlying Index should be at least 35. If there are fewer than 35
stocks, stocks from a supplementary list of highly correlated
sub-industries that meet the market capitalization and liquidity
thresholds above are included in the order of their float-adjusted
market capitalization to reach 35 constituents. Minimum market
capitalization requirements may be relaxed to ensure there are at
least 22 companies in the Underlying Index as of each rebalancing
effective date.
Eligibility factors include:
|
● |
Market Capitalization: Float-adjusted market capitalization
should be at least US$400 million for inclusion in the Underlying
Index. Existing index components must have a float-adjusted market
capitalization of US$300 million to remain in the Underlying Index
at each rebalancing. |
|
● |
Liquidity: The liquidity measurement used is a liquidity ratio,
defined as dollar value traded over the previous 12-months divided
by the float-adjusted market capitalization as of the Underlying
Index rebalancing reference date. Stocks having a float-adjusted
market capitalization above US$500 million must have a liquidity
ratio greater than 90% to be eligible for addition to the
Underlying Index. Stocks having a float-adjusted market
capitalization between US$400 and US$500 million must have a
liquidity ratio greater than 150% to be eligible for addition to
the Underlying Index. Existing index constituents must have a
liquidity ratio greater than 50% to remain in the Underlying Index
at the quarterly rebalancing. The length of time to evaluate
liquidity is reduced to the available trading period for IPOs or
spin-offs that do not have 12 months of trading history. |
|
● |
Takeover Restrictions: At the discretion of S&P®,
constituents with shareholder ownership restrictions defined in
company bylaws may be deemed ineligible for inclusion in the
Underlying Index. Ownership restrictions preventing entities from
replicating the index weight of a company may be excluded from the
eligible universe or removed from the Underlying index. |
|
● |
Turnover: S&P® believes
turnover in index membership should be avoided when possible. At
times, a company may appear to temporarily violate one or more of
the addition criteria. However, the addition criteria are for
addition to the Underlying Index, not for continued membership. As
a result, an index constituent that appears to violate the criteria
for addition to the Underlying Index will not be deleted unless
ongoing conditions warrant a change in the composition of the
Underlying index. |
Historical Performance of the KRE
The following graph sets forth the daily historical performance of
the KRE in the period from January 3, 2017 through January 18,
2022. We obtained this historical data from Bloomberg L.P. We have
not independently verified the accuracy or completeness of the
information obtained from Bloomberg L.P. The horizontal line in the
graph represents the KRE’s hypothetical Coupon Barrier and
Threshold Value of $50.12 (rounded to two decimal places), which is
65% of the KRE’s hypothetical Starting Value of $77.11, which was
its Closing Market Price on January 18, 2022. The actual Starting
Value, Coupon Barrier and Threshold Value will be determined on the
pricing date.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-18 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF

This historical data on the KRE is not necessarily indicative of
the future performance of the KRE or what the value of the Notes
may be. Any historical upward or downward trend in the Closing
Market Price of the KRE during any period set forth above is not an
indication that the Closing Market Price of the KRE is more or less
likely to increase or decrease at any time over the term of the
Notes.
Before investing in the Notes, you should consult publicly
available sources for the Closing Market Prices and trading pattern
of the KRE.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-19 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Supplement to the Plan of Distribution; Role of BofAS and Conflicts
of Interest
BofAS, a broker-dealer affiliate of ours, is a member of the
Financial Industry Regulatory Authority, Inc. (“FINRA”) and will
participate as selling agent in the distribution of the Notes.
Accordingly, the offering of the Notes will conform to the
requirements of FINRA Rule 5121. BofAS may not make sales in this
offering to any of its discretionary accounts without the prior
written approval of the account holder.
We expect to deliver the Notes against payment therefor in New
York, New York on a date that is greater than two business days
following the pricing date. Under Rule 15c6-1 of the Securities
Exchange Act of 1934, trades in the secondary market generally are
required to settle in two business days, unless the parties to any
such trade expressly agree otherwise. Accordingly, if the initial
settlement of the Notes occurs more than two business days from the
pricing date, purchasers who wish to trade the Notes more than two
business days prior to the original issue date will be required to
specify alternative settlement arrangements to prevent a failed
settlement.
Under our distribution agreement with BofAS, BofAS will purchase
the Notes from us as principal at the public offering price
indicated on the cover of this pricing supplement, less the
indicated underwriting discount, if any. BofAS will sell the Notes
to other broker-dealers that will participate in the offering and
that are not affiliated with us, at an agreed discount to the
principal amount. Each of those broker-dealers may sell the Notes
to one or more additional broker-dealers. BofAS has informed us
that these discounts may vary from dealer to dealer and that not
all dealers will purchase or repurchase the Notes at the same
discount. Certain dealers who purchase the Notes for sale to
certain fee-based advisory accounts may forgo some or all of their
selling concessions, fees or commissions. The public offering price
for investors purchasing the Notes in these fee-based advisory
accounts may be as low as $982.50 per $1,000 in principal amount of
Notes.
BofAS and any of our other broker-dealer affiliates may use this
pricing supplement and the accompanying product supplement,
prospectus supplement and prospectus for offers and sales in
secondary market transactions and market-making transactions in the
Notes. However, they are not obligated to engage in such secondary
market transactions and/or market-making transactions. These
broker-dealer affiliates may act as principal or agent in these
transactions, and any such sales will be made at prices related to
prevailing market conditions at the time of the sale.
At BofAS’s discretion, for a short, undetermined initial period
after the issuance of the Notes, BofAS may offer to buy the Notes
in the secondary market at a price that may exceed the initial
estimated value of the Notes. Any price offered by BofAS for the
Notes will be based on then-prevailing market conditions and other
considerations, including the performance of the Underlyings and
the remaining term of the Notes. However, none of us, the
Guarantor, BofAS or any of our other affiliates is obligated to
purchase your Notes at any price or at any time, and we cannot
assure you that any party will purchase your Notes at a price that
equals or exceeds the initial estimated value of the Notes.
Any price that BofAS may pay to repurchase the Notes will depend
upon then prevailing market conditions, the creditworthiness of us
and the Guarantor, and transaction costs. At certain times, this
price may be higher than or lower than the initial estimated value
of the Notes.
European Economic Area and United Kingdom
None of this pricing supplement, the accompanying product
supplement, the accompanying prospectus or the accompanying
prospectus supplement is a prospectus for the purposes of the
Prospectus Regulation (as defined below). This pricing supplement,
the accompanying product supplement, the accompanying prospectus
and the accompanying prospectus supplement have been prepared on
the basis that any offer of Notes in any Member State of the
European Economic Area (the “EEA”) or in the United Kingdom (each,
a “Relevant State”) will only be made to a legal entity which is a
qualified investor under the Prospectus Regulation (“Qualified
Investors”). Accordingly any person making or intending to make an
offer in that Relevant State of Notes which are the subject of the
offering contemplated in this pricing supplement, the accompanying
product supplement, the accompanying prospectus and the
accompanying prospectus supplement may only do so with respect to
Qualified Investors. Neither BofA Finance nor BAC has authorized,
nor does it authorize, the making of any offer of Notes other than
to Qualified Investors. The expression “Prospectus Regulation”
means Regulation (EU) 2017/1129.
PROHIBITION OF SALES TO EEA AND
UNITED KINGDOM RETAIL INVESTORS – The Notes are not
intended to be offered, sold or otherwise made available to and
should not be offered, sold or otherwise made available to any
retail investor in the EEA or in the United Kingdom. For these
purposes: (a) a retail investor means a person who is one (or more)
of: (i) a retail client as defined in point (11) of Article 4(1) of
Directive 2014/65/EU, as amended (“MiFID II”); or (ii) a customer
within the meaning of Directive (EU) 2016/97 (the Insurance
Distribution Directive) where that customer would not qualify as a
professional client as defined in point (10) of Article 4(1) of
MiFID II; or (iii) not a qualified investor as defined in the
Prospectus Regulation; and (b) the expression “offer” includes the
communication in any form and by any means of sufficient
information on the terms of the offer and the Notes to be offered
so as to enable an investor to decide to purchase or subscribe for
the Notes. Consequently no key information document required by
Regulation (EU) No 1286/2014, as amended (the “PRIIPs Regulation”)
for offering or selling the Notes or otherwise making them
available to retail investors in the EEA or in the United Kingdom
has been prepared and therefore offering or selling the Notes or
otherwise making them available to any retail investor in the EEA
or in the United Kingdom may be unlawful under the PRIIPs
Regulation.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-20 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
United Kingdom
The communication of this pricing supplement, the accompanying
product supplement, the accompanying prospectus supplement, the
accompanying prospectus and any other document or materials
relating to the issue of the Notes offered hereby is not being
made, and such documents and/or materials have not been approved,
by an authorized person for the purposes of section 21 of the
United Kingdom’s Financial Services and Markets Act 2000, as
amended (the “FSMA”). Accordingly, such documents and/or materials
are not being distributed to, and must not be passed on to, the
general public in the United Kingdom. The communication of such
documents and/or materials as a financial promotion is only being
made to those persons in the United Kingdom who have professional
experience in matters relating to investments and who fall within
the definition of investment professionals (as defined in Article
19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the “Financial Promotion
Order”)), or who fall within Article 49(2)(a) to (d) of the
Financial Promotion Order, or who are any other persons to whom it
may otherwise lawfully be made under the Financial Promotion Order
(all such persons together being referred to as “relevant
persons”). In the United Kingdom, the Notes offered hereby are only
available to, and any investment or investment activity to which
this pricing supplement, the accompanying product supplement, the
accompanying prospectus supplement and the accompanying prospectus
relates will be engaged in only with, relevant persons. Any person
in the United Kingdom that is not a relevant person should not act
or rely on this pricing supplement, the accompanying product
supplement, the accompanying prospectus supplement or the
accompanying prospectus or any of their contents.
Any invitation or inducement to engage in investment activity
(within the meaning of Section 21 of the FSMA) in connection with
the issue or sale of the Notes may only be communicated or caused
to be communicated in circumstances in which Section 21(1) of the
FSMA does not apply to BofA Finance, as issuer, or BAC, as
guarantor.
All applicable provisions of the FSMA must be complied with in
respect to anything done by any person in relation to the Notes in,
from or otherwise involving the United Kingdom.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-21 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Structuring the Notes
The Notes are our debt securities, the return on which is linked to
the performance of the Underlyings. The related guarantee is BAC’s
obligation. As is the case for all of our and BAC’s respective debt
securities, including our market-linked notes, the economic terms
of the Notes reflect our and BAC’s actual or perceived
creditworthiness at the time of pricing. In addition, because
market-linked notes result in increased operational, funding and
liability management costs to us and BAC, BAC typically borrows the
funds under these types of notes at a rate, which we refer to in
this pricing supplement as BAC’s internal funding rate, that is
more favorable to BAC than the rate that it might pay for a
conventional fixed or floating rate debt security. This generally
relatively lower internal funding rate, which is reflected in the
economic terms of the Notes, along with the fees and charges
associated with market-linked notes, typically results in the
initial estimated value of the Notes on the pricing date being less
than their public offering price.
In order to meet our payment obligations on the Notes, at the time
we issue the Notes, we may choose to enter into certain hedging
arrangements (which may include call options, put options or other
derivatives) with BofAS or one of our other affiliates. The terms
of these hedging arrangements are determined based upon terms
provided by BofAS and its affiliates, and take into account a
number of factors, including our and BAC’s creditworthiness,
interest rate movements, the volatility of the Underlyings, the
tenor of the Notes and the hedging arrangements. The economic terms
of the Notes and their initial estimated value depend in part on
the terms of these hedging arrangements.
BofAS has advised us that the hedging arrangements will include
hedging related charges, reflecting the costs associated with, and
our affiliates’ profit earned from, these hedging arrangements.
Since hedging entails risk and may be influenced by unpredictable
market forces, actual profits or losses from these hedging
transactions may be more or less than any expected amounts.
For further information, see “Risk Factors” beginning on page PS-8
above and “Supplemental Use of Proceeds” on page PS-19 of the
accompanying product supplement.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-22 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
U.S. Federal Income Tax Summary
The following summary of the material U.S. federal income and
estate tax considerations of the acquisition, ownership, and
disposition of the Notes supplements, and to the extent
inconsistent supersedes, the discussions under “U.S. Federal Income
Tax Considerations” in the accompanying prospectus and under “U.S.
Federal Income Tax Considerations” in the accompanying prospectus
supplement and is not exhaustive of all possible tax
considerations. This summary is based upon the Internal Revenue
Code of 1986, as amended (the “Code”), regulations promulgated
under the Code by the U.S. Treasury Department (“Treasury”)
(including proposed and temporary regulations), rulings, current
administrative interpretations and official pronouncements of the
IRS, and judicial decisions, all as currently in effect and all of
which are subject to differing interpretations or to change,
possibly with retroactive effect. No assurance can be given that
the IRS would not assert, or that a court would not sustain, a
position contrary to any of the tax consequences described below.
This summary does not include any description of the tax laws of
any state or local governments, or of any foreign government, that
may be applicable to a particular holder.
Although the Notes are issued by us, they will be treated as if
they were issued by BAC for U.S. federal income tax purposes.
Accordingly throughout this tax discussion, references to “we,”
“our” or “us” are generally to BAC unless the context requires
otherwise.
This summary is directed solely to U.S. Holders and Non-U.S.
Holders that, except as otherwise specifically noted, will purchase
the Notes upon original issuance and will hold the Notes as capital
assets within the meaning of Section 1221 of the Code, which
generally means property held for investment, and that are not
excluded from the discussion under “U.S. Federal Income Tax
Considerations” in the accompanying prospectus.
You should consult your own tax advisor concerning the U.S. federal
income tax consequences to you of acquiring, owning, and disposing
of the Notes, as well as any tax consequences arising under the
laws of any state, local, foreign, or other tax jurisdiction and
the possible effects of changes in U.S. federal or other tax
laws.
General
Although there is no statutory, judicial, or administrative
authority directly addressing the characterization of the Notes, we
intend to treat the Notes for all tax purposes as contingent
income-bearing single financial contracts with respect to the
Underlyings and under the terms of the Notes, we and every investor
in the Notes agree, in the absence of an administrative
determination or judicial ruling to the contrary, to treat the
Notes in accordance with such characterization. In the opinion of
our counsel, Sidley Austin LLP, it is reasonable to treat the Notes
as contingent income-bearing single financial contracts with
respect to the Underlyings. However, Sidley Austin LLP has advised
us that it is unable to conclude that it is more likely than not
that this treatment will be upheld. This discussion assumes that
the Notes constitute contingent income-bearing single financial
contracts with respect to the Underlyings for U.S. federal income
tax purposes. If the Notes did not constitute contingent
income-bearing single financial contracts, the tax consequences
described below would be materially different.
This characterization of the Notes is not binding on the IRS or
the courts. No statutory, judicial, or administrative authority
directly addresses the characterization of the Notes or any similar
instruments for U.S. federal income tax purposes, and no ruling is
being requested from the IRS with respect to their proper
characterization and treatment. Due to the absence of authorities
on point, significant aspects of the U.S. federal income tax
consequences of an investment in the Notes are not certain, and no
assurance can be given that the IRS or any court will agree with
the characterization and tax treatment described in this pricing
supplement. Accordingly, you are urged to consult your tax advisor
regarding all aspects of the U.S. federal income tax consequences
of an investment in the Notes, including possible alternative
characterizations.
Unless otherwise stated, the following discussion is based on the
characterization described above. The discussion in this section
assumes that there is a significant possibility of a significant
loss of principal on an investment in the Notes.
We will not attempt to ascertain whether the issuer of any
Underlying would be treated as a “passive foreign investment
company” (“PFIC”), within the meaning of Section 1297 of the Code,
or a United States real property holding corporation, within the
meaning of Section 897(c) of the Code. If the issuer of any
Underlying were so treated, certain adverse U.S. federal income tax
consequences could possibly apply to a holder of the Notes. You
should refer to information filed with the SEC by the issuers of
the Underlyings and consult your tax advisor regarding the possible
consequences to you, if any, if the issuer of any Underlying is or
becomes a PFIC or is or becomes a United States real property
holding corporation.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-23 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
U.S. Holders
Although the U.S. federal income tax treatment of any Contingent
Coupon Payment on the Notes is uncertain, we intend to take the
position, and the following discussion assumes, that any Contingent
Coupon Payment constitutes taxable ordinary income to a U.S. Holder
at the time received or accrued in accordance with the U.S.
Holder’s regular method of accounting. By purchasing the Notes you
agree, in the absence of an administrative determination or
judicial ruling to the contrary, to treat any Contingent Coupon
Payment as described in the preceding sentence.
Upon receipt of a cash payment at maturity or upon a sale,
exchange, or redemption of the Notes prior to maturity, a U.S.
Holder generally will recognize capital gain or loss equal to the
difference between the amount realized (other than amounts
representing any Contingent Coupon Payment, which would be taxed as
described above) and the U.S. Holder’s tax basis in the Notes. A
U.S. Holder’s tax basis in the Notes will equal the amount paid by
that holder to acquire them. Subject to the discussion below
concerning the possible application of the “constructive ownership”
rules of Section 1260 of the Code, this capital gain or loss
generally will be long-term capital gain or loss if the U.S. Holder
held the Notes for more than one year. The deductibility of capital
losses is subject to limitations.
Possible Application of Section 1260 of the Code. Since each
Underlying is the type of financial asset described under Section
1260 of the Code (including, among others, any equity interest in
pass-through entities such as exchange traded funds, regulated
investment companies, real estate investment trusts, partnerships,
and passive foreign investment companies, each a “Section 1260
Financial Asset”), while the matter is not entirely clear, there
may exist a risk that an investment in the Notes will be treated,
in whole or in part, as a “constructive ownership transaction” to
which Section 1260 of the Code applies. If Section 1260 of the Code
applies, all or a portion of any long-term capital gain recognized
by a U.S. Holder in respect of the Notes will be recharacterized as
ordinary income (the “Excess Gain”). In addition, an interest
charge will also apply to any deemed underpayment of tax in respect
of any Excess Gain to the extent such gain would have resulted in
gross income inclusion for the U.S. Holder in taxable years prior
to the taxable year of the sale, exchange, redemption, or
settlement (assuming such income accrued at a constant rate equal
to the applicable federal rate as of the date of sale, exchange,
redemption, or settlement).
If an investment in the Notes is treated as a constructive
ownership transaction, it is not clear to what extent any long-term
capital gain of a U.S. Holder in respect of the Notes will be
recharacterized as ordinary income. It is possible, for example,
that the amount of the Excess Gain (if any) that would be
recharacterized as ordinary income in respect of the Notes will
equal the excess of (i) any long-term capital gain recognized by
the U.S. Holder in respect of the Notes and attributable to Section
1260 Financial Assets, over (ii) the “net underlying long-term
capital gain” (as defined in Section 1260 of the Code) such U.S.
Holder would have had if such U.S. Holder had acquired an amount of
the corresponding Section 1260 Financial Assets at fair market
value on the original issue date for an amount equal to the portion
of the issue price of the Notes attributable to the corresponding
Section 1260 Financial Assets and sold such amount of Section 1260
Financial Assets at maturity or upon sale or exchange of the Notes
at fair market value. Unless otherwise established by clear and
convincing evidence, the net underlying long-term capital gain is
treated as zero and therefore it is possible that all long-term
capital gain recognized by a U.S. Holder in respect of the Notes
will be recharacterized as ordinary income if Section 1260 of the
Code applies to an investment in the Notes. U.S. Holders should
consult their tax advisors regarding the potential application of
Section 1260 of the Code to an investment in the Notes.
As described below, the IRS, as indicated in Notice 2008-2 (the
“Notice”), is considering whether Section 1260 of the Code
generally applies or should apply to the Notes, including in
situations where the Underlyings are not the type of financial
asset described under Section 1260 of the Code.
Alternative Tax Treatments. Due to the absence of
authorities that directly address the proper tax treatment of the
Notes, prospective investors are urged to consult their tax
advisors regarding all possible alternative tax treatments of an
investment in the Notes. In particular, the IRS could seek to
subject the Notes to the Treasury regulations governing contingent
payment debt instruments. If the IRS were successful in that
regard, the timing and character of income on the Notes would be
affected significantly. Among other things, a U.S. Holder would be
required to accrue original issue discount every year at a
“comparable yield” determined at the time of issuance. In addition,
any gain realized by a U.S. Holder at maturity or upon a sale,
exchange, or redemption of the Notes generally would be treated as
ordinary income, and any loss realized at maturity or upon a sale,
exchange, or redemption of the Notes generally would be treated as
ordinary loss to the extent of the U.S. Holder’s prior accruals of
original issue discount, and as capital loss thereafter.
In addition, it is possible that the Notes could be treated as a
unit consisting of a deposit and a put option written by the Note
holder, in which case the timing and character of income on the
Notes would be affected significantly.
The Notice sought comments from the public on the taxation of
financial instruments currently taxed as “prepaid forward
contracts.” This Notice addresses instruments such as the Notes.
According to the Notice, the IRS and Treasury are considering
whether a holder of an instrument such as the Notes should be
required to accrue ordinary income on a current basis, regardless
of whether any payments are made prior to maturity. It is not
possible to determine what guidance the IRS and Treasury will
ultimately issue, if any. Any such future guidance may affect the
amount, timing and character of income, gain, or loss in respect of
the Notes, possibly with retroactive effect.
The IRS and Treasury are also considering additional issues,
including whether additional gain or loss from such instruments
should be treated as ordinary or capital, whether foreign holders
of such instruments should be subject to withholding tax on any
deemed income accruals, whether Section
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-24 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
1260 of the Code, concerning certain “constructive ownership
transactions,” generally applies or should generally apply to such
instruments, and whether any of these determinations depend on the
nature of the underlying asset.
In addition, proposed Treasury regulations require the accrual of
income on a current basis for contingent payments made under
certain notional principal contracts. The preamble to the
regulations states that the “wait and see” method of accounting
does not properly reflect the economic accrual of income on those
contracts, and requires current accrual of income for some
contracts already in existence. While the proposed regulations do
not apply to prepaid forward contracts, the preamble to the
proposed regulations expresses the view that similar timing issues
exist in the case of prepaid forward contracts. If the IRS or
Treasury publishes future guidance requiring current economic
accrual for contingent payments on prepaid forward contracts, it is
possible that you could be required to accrue income over the term
of the Notes.
Because of the absence of authority regarding the appropriate tax
characterization of the Notes, it is also possible that the IRS
could seek to characterize the Notes in a manner that results in
tax consequences that are different from those described above. For
example, the IRS could possibly assert that any gain or loss that a
holder may recognize at maturity or upon the sale, exchange, or
redemption of the Notes should be treated as ordinary gain or
loss.
Non-U.S. Holders
Because the U.S. federal income tax treatment of the Notes
(including any Contingent Coupon Payment) is uncertain, we (or the
applicable paying agent) will withhold U.S. federal income tax at a
30% rate (or at a lower rate under an applicable income tax treaty)
on the entire amount of any Contingent Coupon Payment made unless
such payments are effectively connected with the conduct by the
Non-U.S. Holder of a trade or business in the U.S. (in which case,
to avoid withholding, the Non-U.S. Holder will be required to
provide a Form W-8ECI). We (or the applicable paying agent) will
not pay any additional amounts in respect of such withholding. To
claim benefits under an income tax treaty, a Non-U.S. Holder must
obtain a taxpayer identification number and certify as to its
eligibility under the appropriate treaty’s limitations on benefits
article, if applicable. In addition, special rules may apply to
claims for treaty benefits made by Non-U.S. Holders that are
entities rather than individuals. The availability of a lower rate
of withholding under an applicable income tax treaty will depend on
whether such rate applies to the characterization of the payments
under U.S. federal income tax laws. A Non-U.S. Holder that is
eligible for a reduced rate of U.S. federal withholding tax
pursuant to an income tax treaty may obtain a refund of any excess
amounts withheld by filing an appropriate claim for refund with the
IRS.
Except as discussed below, a Non-U.S. Holder generally will not be
subject to U.S. federal income or withholding tax for amounts paid
in respect of the Notes (not including, for the avoidance of doubt,
amounts representing any Contingent Coupon Payment which would be
subject to the rules discussed in the previous paragraph) upon the
sale, exchange, or redemption of the Notes or their settlement at
maturity, provided that the Non-U.S. Holder complies with
applicable certification requirements and that the payment is not
effectively connected with the conduct by the Non-U.S. Holder of a
U.S. trade or business. Notwithstanding the foregoing, gain from
the sale, exchange, or redemption of the Notes or their settlement
at maturity may be subject to U.S. federal income tax if that
Non-U.S. Holder is a non-resident alien individual and is present
in the U.S. for 183 days or more during the taxable year of the
sale, exchange, redemption, or settlement and certain other
conditions are satisfied.
If a Non-U.S. Holder of the Notes is engaged in the conduct of a
trade or business within the U.S. and if any Contingent Coupon
Payment and gain realized on the settlement at maturity, or upon
sale, exchange, or redemption of the Notes, is effectively
connected with the conduct of such trade or business (and, if
certain tax treaties apply, is attributable to a permanent
establishment maintained by the Non-U.S. Holder in the U.S.), the
Non-U.S. Holder, although exempt from U.S. federal withholding tax,
generally will be subject to U.S. federal income tax on such
Contingent Coupon Payment and gain on a net income basis in the
same manner as if it were a U.S. Holder. Such Non-U.S. Holders
should read the material under the heading “—U.S. Holders,” for a
description of the U.S. federal income tax consequences of
acquiring, owning, and disposing of the Notes. In addition, if such
Non-U.S. Holder is a foreign corporation, it may also be subject to
a branch profits tax equal to 30% (or such lower rate provided by
any applicable tax treaty) of a portion of its earnings and profits
for the taxable year that are effectively connected with its
conduct of a trade or business in the U.S., subject to certain
adjustments.
A “dividend equivalent” payment is treated as a dividend from
sources within the United States and such payments generally would
be subject to a 30% U.S. withholding tax if paid to a Non-U.S.
Holder. Under Treasury regulations, payments (including deemed
payments) with respect to equity-linked instruments (“ELIs”) that
are “specified ELIs” may be treated as dividend equivalents if such
specified ELIs reference an interest in an “underlying security,”
which is generally any interest in an entity taxable as a
corporation for U.S. federal income tax purposes if a payment with
respect to such interest could give rise to a U.S. source dividend.
However, IRS guidance provides that withholding on dividend
equivalent payments will not apply to specified ELIs that are not
delta-one instruments and that are issued before January 1, 2023.
Based on our determination that the Notes are not delta-one
instruments, Non-U.S. Holders should not be subject to withholding
on dividend equivalent payments, if any, under the Notes. However,
it is possible that the Notes could be treated as deemed reissued
for U.S. federal income tax purposes upon the occurrence of certain
events affecting the Underlyings or the Notes, and following such
occurrence the Notes could be treated as subject to withholding on
dividend equivalent payments. Non-U.S. Holders that enter, or have
entered, into other transactions in respect of the Underlyings or
the Notes should consult their tax advisors as to the application
of the dividend equivalent withholding tax in the context of the
Notes and their other transactions. If any payments are treated as
dividend equivalents subject to withholding, we (or the applicable
paying agent) would be entitled to withhold taxes without being
required to pay any additional amounts with respect to amounts so
withheld.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-25 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
As discussed above, alternative characterizations of the Notes for
U.S. federal income tax purposes are possible. Should an
alternative characterization, by reason of change or clarification
of the law, by regulation or otherwise, cause payments as to the
Notes to become subject to withholding tax in addition to the
withholding tax described above, tax will be withheld at the
applicable statutory rate. Prospective Non-U.S. Holders should
consult their own tax advisors regarding the tax consequences of
such alternative characterizations.
U.S. Federal Estate Tax. Under current law, while the matter
is not entirely clear, individual Non-U.S. Holders, and entities
whose property is potentially includible in those individuals’
gross estates for U.S. federal estate tax purposes (for example, a
trust funded by such an individual and with respect to which the
individual has retained certain interests or powers), should note
that, absent an applicable treaty benefit, a Note is likely to be
treated as U.S. situs property, subject to U.S. federal estate tax.
These individuals and entities should consult their own tax
advisors regarding the U.S. federal estate tax consequences of
investing in a Note.
Backup Withholding and Information Reporting
Please see the discussion under “U.S. Federal Income Tax
Considerations — General — Backup Withholding and Information
Reporting” in the accompanying prospectus for a description of the
applicability of the backup withholding and information reporting
rules to payments made on the Notes.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-26 |
Contingent Income Issuer Callable Yield Notes Linked to the Least
Performing of the INDUSTRIAL SELECT SECTOR SPDR FUND, the SPDR
S&P BIOTECH ETF and the SPDR S&P REGIONAL BANKING ETF
Where You Can Find More Information
The terms and risks of the Notes are contained in this pricing
supplement and in the following related product supplement,
prospectus supplement and prospectus, which can be accessed at the
following links:
This pricing supplement and the accompanying product supplement,
prospectus supplement and prospectus have been filed as part of a
registration statement with the SEC, which may, without cost, be
accessed on the SEC website at www.sec.gov or obtained from BofAS
by calling 1-800-294-1322. Before you invest, you should read this
pricing supplement and the accompanying product supplement,
prospectus supplement and prospectus for information about us, BAC
and this offering. Any prior or contemporaneous oral statements and
any other written materials you may have received are superseded by
this pricing supplement and the accompanying product supplement,
prospectus supplement and prospectus. Certain terms used but not
defined in this pricing supplement have the meanings set forth in
the accompanying product supplement or prospectus supplement.
Unless otherwise indicated or unless the context requires
otherwise, all references in this document to “we,” “us,” “our,” or
similar references are to BofA Finance, and not to BAC.
The Notes are our senior debt securities. Any payments on the Notes
are fully and unconditionally guaranteed by BAC. The Notes and the
related guarantee are not insured by the Federal Deposit Insurance
Corporation or secured by collateral. The Notes will rank equally
in right of payment with all of our other unsecured and
unsubordinated obligations, and the related guarantee will rank
equally in right of payment with all of BAC’s other unsecured and
unsubordinated obligations, in each case except obligations that
are subject to any priorities or preferences by law. Any payments
due on the Notes, including any repayment of the principal amount,
will be subject to the credit risk of BofA Finance, as issuer, and
BAC, as guarantor.
|
CONTINGENT INCOME ISSUER CALLABLE YIELD
NOTES | PS-27 |
Bank of America (NYSE:BAC)
Historical Stock Chart
From Apr 2022 to May 2022
Bank of America (NYSE:BAC)
Historical Stock Chart
From May 2021 to May 2022